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Multiple Human Papillomavirus Infection Is Associated with 
High-Risk Infection in Male Genital Warts in Ulsan, Korea
Further understanding of male human papillomavirus (HPV) infection is necessary to 
prevent infection in men, as well as transmission to women. In our current study, we 
investigated patterns of HPV infection and genotype distributions in male genital warts 
using the Anyplex II HPV28 Detection kit. We reviewed the medical records of 80 male 
patients who presented to 5 neighborhood clinics in Ulsan, Korea, for the treatment of 
genital warts between April 2014 and January 2015. All patients underwent HPV 
genotyping. The prevalence and characteristics of HPV infection were analyzed, and the 
patterns of HPV infection according to age were assessed. Among the study patients, 13 
(16.3%) were negative for HPV infection, 46 (57.3%) were infected with low-risk HPV, 
and 21 (26.3%) were infected with high-risk HPV. Patients with multiple HPV infection 
were more likely to have high-risk HPV infection (P = 0.001). The prevalence of HPV 
infection was much higher in samples obtained by tissue excision due to a definite lesion 
(P = 0.001). There were no differences in high-risk HPV infection (P = 0.459), multiple HPV 
infection (P = 0.185), and recurrence at diagnosis (P = 0.178) according to age. HPV-6 
and HPV-11 were the most common type overall (39.7% and 13.8%, respectively). HPV-
16 and HPV-18 were the most common high-risk infections (both 3.4%). HPV infection is 
not only commonly encountered in male genital warts, but is also accompanied by high-
risk HPV and multiple infections.
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INTRODUCTION
Human papillomavirus (HPV) is the most common sexually 
transmitted pathogen and is the cause of various urogenital 
cancers (1,2). Approximately 60 HPV genotypes are known to 
infect the genital tract and at least 13 of these are considered 
‘‘high-risk’’ or oncogenic (1,3). Although infection is mostly 
transient and asymptomatic, oncogenic genotypes of HPV are 
related with cervical cancer development and other urogenital 
cancers in both men and women (4). Meanwhile, low-risk HPV 
types cause genital warts and other benign lesions (5). HPV co-
infection or sequential infections with multiple HPV types re-
portedly synergistically increase the risk of cervical cancer (6). 
Patients infected with multiple HPV types require intensive 
care to prevent cancer progression and death, which indicates 
that monitoring the genotype and quantity of HPV may provide 
critical information in the diagnosis of infections for future pa-
tient management and prognosis (7).
 The advance of helpful prophylactic vaccines against HPV 
types 16 and 18 has significantly foremost the prevention of 
cervical cancer, the second most common cancer in women 
worldwide (8,9). Moreover, there has been increasing interest 
in expansion HPV vaccination to men, in whom genital warts 
and oropharyngeal, penile, and anal cancers are also symptoms 
of HPV infection (10,11). Therefore, full HPV genotyping is not 
only useful clinically to identify patients with type-specific high-
risk HPV infections that confer a higher risk of cancer progres-
sion, but also to identify patients in whom vaccination is an ef-
fective prevention. The Anyplex II HPV28 Detection kit is de-
signed for HPV genotyping and quantitation to meet the cur-
rent demands for HPV detection. It simultaneously detects 19 
high-risk HPV types (types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 
53, 56, 58, 59, 66, 68, 69, 73, and 82) and 9 low-risk HPV types 
(types 6, 11, 40, 42, 43, 44, 54, 61, and 70) from a single speci-
men using Tagging Oligonucleotide Cleavage and Extension 
(TOCE) technology.
 Moreover, although genital HPV infections have been exten-
sively studied in different groups of women, HPV infection in 
men is still not fully understood (12,13). Further understanding 
of male HPV infection is necessary to prevent infection in men, 
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as well as transmission to women. In our current study, we in-
vestigated the patterns of HPV infection and genotype distribu-
tions in male genital warts using Anyplex II HPV28 Detection.
MATERIALS AND METHODS
Study participants
The medical records of 80 male patients who presented to the 5 
neighborhood clinics of Ulsan, Korea, between April 2014 and 
January 2015 for the treatment of genital warts were reviewed. 
All patients underwent HPV genotyping using Anyplex II HPV28 
Detection. The following information on patterns of HPV infec-
tion was retrieved from the medical records of all patients: age, 
lesion location, methods of sample acquisition, types of HPV, 
and history of HPV. Multiple HPV infection was defined as co-
infection with 2 or more types of HPV. Based on the type of HPV, 
patients were divided into 3 groups: no HPV infection, low-risk 
HPV infection, and high-risk HPV infection.
Collection of biologic samples
The collection of exfoliated genital cells from patients was per-
formed by surgical excision of tissue or by cytobrush scratching. 
The cytobrush was moistened with phosphate-buffered saline 
and used to brush the penis, in a continuously rotational move-
ment, from bottom to top, starting at the middle third of the scro-
tum. After retraction of the prepuce (in uncircumcised males), 
the coronal sulcus, the glans, and the tip of the penis also were 
brushed. The brush was cut and placed in a tube containing 5 
mL of phosphate-buffered saline. Finally, a premoistened Da-
cron swab was gently rotated into the urethral opening and was 
placed in the same tube.
DNA extraction, HPV detection and genotyping
Nucleic acids were extracted from a 400 µL sample using the 
MICROLAB STARlet automated purification system (Hamilton, 
Reno, NV, USA). HPV detection and genotyping were performed 
according to the manufacturer’s instructions using the Anyplex 
II HPV28 kit and a CFX96 real-time thermocycler (Bio-Rad, Her-
cules, CA, USA). TOCE technology (Seegene, Seoul, Korea) is a 
novel approach that enables the detection of multiple targets in 
the same fluorescence channel of real-time PCR instruments 
using 2 components, “Pitcher” and “Catcher”. Taq polymerase 
extends from a target specific primer and encounters the target-
bound Pitcher, which is cleaved by 5’ nuclease activity, releas-
ing the Tagging portion. The sequence of the released Tagging 
portion is complementary to the capturing portion of the Catch-
er. TOCE assay uses a predetermined target sequence specific 
to the Catcher, enabling predictable analysis of the melting tem-
perature of the Catcher duplex and providing multiplex real-
time PCR capability to HPV28. In addition to amplification of 
the L1 gene of HPV DNA, the human housekeeping gene (hu-
man beta-globin) was simultaneously co-amplified as an inter-
nal control to monitor DNA purification efficiency, PCR inhibi-
tion, and cell adequacy. The thermal cycler conditions consist-
ed of an initial incubation at 50°C for 4 minutes to activate the 
uracil DNA glycosylase system in order to prevent contamination 
and denaturation at 95°C for 15 minutes, followed by 50 cycles 
of denaturation at 95°C for 30 seconds, annealing at 60°C for 1 
minute, and elongation at 72°C for 30 seconds. The fluorescence 
was measured continuously as the temperature incre ased.
 The Anyplex II HPV28 consists of 2 sets: the A set has 14 high-
risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) 
and the B set covers 5 high-risk and 9 low-risk types (26, 53, 69, 
73, 82, 6, 11, 40, 42, 43, 44, 54, 61, and 70). In addition, knowl-
edge of the step at which the melting curve becomes positive 
allowed us to semiquantify the viral load, from low (+; positive 
after 40 PCR cycles), to intermediate (++; positive within 31 to 
39 cycles), to high (+++; positive before 31 cycles). HPV28 thus 
semiquantitatively distinguishes 28 HPV genotypes. Data re-
cording and interpretation were automated with the Seegene 
viewer software according to the manufacturer’s instructions.
Statistical analysis
The 3 study patient groups were compared using the χ2 test or 
the Fisher-Freeman-Halton test for categorical variables and 
the Kruskal-Wallis test for continuous variables. Quantitative 
data were expressed as mean ± standard deviation. The pat-
terns of HPV infection according to age were also assessed. All 
statistical tests were 2-sided, with P < 0.05 considered signifi-
cant. Data were analyzed using IBM SPSS Statistics Version 21 
(IBM Corporation, Somers, NY, USA).
Ethics statement
This study was approved by institutional review board of Seoul 
Asan Medical Center (IRB No. 2015-06-029). Clinical data were 
obtained by retrospective review of the medical records of all of 
the included patients and the requirement for informed con-
sent was therefore waived.
RESULTS
The descriptive characteristics of the 80 study patients are shown 
in Table 1. Of these patients, there were 13 (16.3%) whose speci-
mens were negative for HPV infection, while 46 (57.3%) were 
infected with low-risk HPV, and 21 (26.3%) were infected with 
high-risk HPV. The mean age of all patients was 35.4 years and 
there were few differences among the groups. Although most of 
the samples were obtained from the penile shaft (75.0%), sam-
ples obtained at the urethra were more likely to have high-risk 
HPV infection (P = 0.017). Patients with multiple HPV infection 
were also more likely to have high-risk HPV infection (P = 0.001). 
The prevalence of HPV infection was much higher in samples 
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obtained by tissue excision due to a definite lesion (P = 0.001). 
Infection recurrence was found in 34 patients (42.5%) at diag-
nosis, mostly of high-risk HPV infection.
 The patterns of HPV infection according to age are shown in 
Table 2. There were no differences in high-risk HPV infection 
(P = 0.459), multiple HPV infection (P = 0.185), and recurrence 
at diagnosis (P = 0.178) according to age. Type-specific infec-
tions by genotyping are shown in Fig. 1. HPV-6 and HPV-11 were 
the most common type detected overall (39.7% and 13.8%, re-
spectively). HPV-16 and HPV-18 were the most common high-
risk HPV infections (both 3.4%).
DISCUSSION
Several research have reported estimates of HPV prevalence 
among men; however, these estimates range widely from 10% 
to 70% (14). Significant differences to the synthesis and inter-
pretation of these studies are the discordance of sampling tech-
niques used, the diversity and combinations of sites and speci-
mens sampled, and the different HPV types tested. Moreover, 
few studies have assessed HPV prevalence in men with genital 
warts. In our present study, 67 (83.7%) of the 80 men with geni-
tal warts were infected with HPV. This rate is much greater than 
that observed previously in asymptomatic men recruited from 
the general population (15). Our current findings suggest that 
patients with genital warts should undergo HPV testing. Also, 
the relatively high rate of HPV prevalence in men with genital 
warts might be attributable to several features of HPV. Low-risk 
HPV types were the main causes of genital warts and patients 
with genital warts have been shown to also have a HPV co-in-
fection or sequential infections of multiple HPV types.
 The presence of multiple HPV types was found previously to 
be the most important risk factor for subsequent acquisition of 
a new HPV type, recurrence, and cancer progression (6,12). Al-
though it has been hypothesized that the acquisition of one HPV 
type facilitates the acquisition of another type by some yet un-
known biological mechanism, it is important that these HPV-
positive men who acquired a new type were more likely to ac-
quire multiple HPV types than HPV-negative men who acquir-
ed HPV during follow-up. This was especially evident for the 
high-risk HPV infection in our current study. Among all of our 
present patients, 32 cases (40%) had multiple HPV infection 
and all of the 21 patients with high-risk HPV infection had mul-
tiple HPV infection. In addition, the incidence of multiple HPV 
infection varies and is related to the method of HPV detection. 
In previous reports, the rate of multiple HPV infection in men 
ranged from 10% to 20% (15,16). These differences may be due 
to the type of sample and the molecular techniques used for 
HPV detection. In our current analyses, most of the samples 
were obtained via tissue excision due to a definite lesion and 
HPV infection was assessed by multiplex real-time PCR. Given 
the dangers of multiple HPV infection and co-infection or se-
quential infections of HPV, genotyping is necessary to determine 
Table 1. Characteristics of study cohorts according to oncogenic risk
Parameters Total No HPV Low risk High risk P value
No. (%) 80 13 (16.3) 46 (57.3) 21 (26.3)
Mean age ± SD (yr) 35.4 ± 9.8 36.3 ± 11.7 34.1 ± 7.5 37.6 ± 12.6 0.359
Site, No. (%)
   Glans
   Shaft
   Scrotum
   Urethra
3 (3.8)
60 (75.0)
13 (16.3)
4 (5.0)
1 (7.7)
8 (61.5)
4 (30.8)
0
2 (4.3)
37 (80.4)
7 (15.2)
0 (0)
0 (0)
15 (71.4)
2 (9.5)
4 (19.0)
0.017
Type of acquisition sample, No. (%)
  Tissue
  Scratching
66 (82.5)
14 (17.5)
3 (23.1)
10 (76.9)
43 (93.5) 
3 (6.5)
20 (95.2)
1 (4.8)
0.001
Multiple infections, No. (%) 32 (40.0) 0 (0) 11 (23.9) 21 (100) 0.001
Recurrence, No. (%) 34 (42.5) 3 (23.1) 18 (39.1) 13 (61.9) 0.065
Partner infection, No. (%) 5 (6.3) 0 3 (6.5) 2 (9.5) 0.534
HPV, human papilloma virus; SD, standard deviation.
Table 2. Patterns of HPV infection according to age
Age group Total No. (%) High risk infection Multi infections Recurrence
≤ 30 yr 28 (35.0) 8 (38.1) 14 (43.7) 10 (29.4)
31–40 yr 31 (38.8) 6 (28.6) 10 (31.3) 12 (35.3)
41–50 yr 15 (18.8) 4 (19.0) 4 (12.5) 7 (20.6)
≥ 51 yr 6 (7.5) 3 (14.3) 4 (12.5) 5 (14.7)
P value 0.459 0.185 0.178
Fig. 1. Distribution of HPV genotypes in the current study cohort.
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the appropriate treatment.
 HPVs are subdivided into low-risk and high-risk variants based 
on the potential for oncogenesis. Genital warts are caused by 
the low-risk types of HPV (6, 11, 42, 43, and 44) with 90% of these 
cases caused by 2 genotypes, HPV-6 and HPV-11 (17). In con-
trast, high-risk HPVs cause cervical carcinomas and urogenital 
cancers. One study has shown that 31% of adults suffering from 
carcinoma are co-infected with a high-risk HPV (18). In our 
present study, HPV-16 and HPV-18 were the most common 
causes of high-risk HPV infections. Few data on HPV-16/-18 
prevalence are available among men for whom current HPV 
prophylactic vaccines are approved (10,11,16). These data would 
be useful to estimate the proportion of men positive for both 
HPV-16/-18 and who thus may obtain optimal benefits from 
HPV vaccination. This also supports efforts to extend HPV vac-
cination to men.
 HPV prevalence might be high among sexually active young 
men and women because it is one of the most common sexual-
ly transmitted infections worldwide (2). However, global data 
on the age-specific prevalence of HPV infection in males show 
a more stable HPV prevalence by age in men than in women 
(19). These data also show similar age-related trends across ma-
jor regions. Similarly, there were no differences in the patterns 
of HPV infection such as high-risk HPV infection and multiple 
HPV infection according to age in our current study series. There-
fore, HPV testing is necessary for genital wart treatment, regard-
less of age.
 The anatomical sites and genotyping methods used for HPV 
detection have varied across different studies and may have 
contributed to the observed differences among men in these 
reports (20,21). In our current study, most of the samples were 
obtained at the penile shaft (75.0%). These findings emphasized 
the importance of the penile shaft as a site of HPV infection in 
men, as well as being a site with the most potential for HPV trans-
mission during sexual intercourse. In addition, our finding that 
samples obtained at the urethra were more likely to have high-
risk infection suggests that men with genital warts should un-
dergo urethral examination. Comparisons of HPV prevalence 
among studies are also hampered by differences among the 
study populations surveyed, laboratory methods used, and HPV 
types analyzed. To reduce possible underestimation of overall 
or type-specific prevalence, we used the Anyplex II HPV28 De-
tection multiplex real-time PCR assay. Although this assay has 
a relatively higher sensitivity for HPV detection than earlier de-
tection assays, the sensitivity of HPV detection presented by our 
present data might have been optimal if the chosen type-spe-
cific PCR primers included typing for only a relatively small num-
ber of HPV types (22,23).
 Our present study findings were limited by the retrospective 
nature of our analyses, our relatively small study cohort, and 
the significant differences among the patients in terms of sever-
al clinical variables. Second, our data were limited to cross-sec-
tional prevalence, rather than the identification of persistent 
HPV infection, which has been shown to be highly predictive of 
the future risk of cancer (24). Moreover, we did not evaluate the 
treatment outcomes or the prognosis. Finally, the current study 
represents patients from six institutions in Ulsan, Korea; there-
fore, differences in technique and decision-making are possi-
ble. Furthermore, our findings may have resulted from limita-
tions in the regional case study. Lager studies including a broad-
er region, applying HPV detection at several time points, are 
needed to confirm our study. Nonetheless, our report is the mean-
ingful study to analyze the patterns of HPV infection and geno-
type distributions in male genital warts using the Anyplex II 
HPV28 Detection kit. Above all, a wide range of ages was en-
rolled in our current study. Also, we found that multiple HPV 
infection is associated with high-risk infection which is most 
important risk factor for subsequent acquisition of a new HPV 
type, recurrence, and cancer progression.
 In conclusions, HPV infection is not only commonly encoun-
tered in male genital warts, but is also accompanied by high-
risk HPV and multiple infections. There are no differences in 
patterns of HPV infection according to age. Although HPV-16/-
18 infections, which can cause urogenital cancer, are the most 
common high-risk HPV infections and no current antiviral ther-
apy exists, prophylactic vaccines for HPV-16/-18 have been ap-
proved. HPV genotyping, regardless of age, is therefore a logical 
first step in the clinical strategy to avoid or minimize potential 
HPV-related carcinogenesis and harm from male genital warts. 
However, our present study cohort was relatively small and fur-
ther studies are needed to fully determine the prognosis of HPV 
infection.
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